{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_9453835_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"022-235-415-635-492","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8878,"type":"PATENT","title":"Kyoto University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":10470,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8212,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately = \"Kyoto University\", \"Kyoto Univ\", \" Univ Kyoto\", \" University Kyoto\", \"Kyot* Univ*\", \"Univ* Kyot*\".
Select more for variants
Add to collection
Select the collection expanded by simple families
Add to collection
Search Applicants and Owners separately = \"Kyoto University\", \"Kyoto Univ\", \" Univ Kyoto\", \" University Kyoto\", \"Kyot* Univ*\", \"Univ* Kyot*\".
Select more for variants
Add to collection
Select the collection expanded by simple families
Add to collection
(1) treating TMEM16F deficient cells into which a gene encoding and expressing the TMEM16 family member selected from the group consisting of TMEM16C, TMEM16D, TMEM16G and TEMEM16J has been introduced with a candidate of the agent in the presence of Ca2+, and\n
(2) determining whether the candidate alters distribution of a lipid selected from the group consisting of phosphatidylserine, phosphatidylcholine, and galactosylceramide in plasma membrane of the cells,\n
wherein a candidate which significantly increases distribution of phosphatidylserine in the outer leaflet of plasma membrane compared to control is selected as an agent promoting a biological function of the TMEM16 family member as a lipid scramblase, and a candidate significantly which decreases distribution of phosphatidylserine in the outer leaflet of plasma membrane compared to control is selected as an agent inhibiting a biological function of the TMEM16 family member as a lipid scramblase, and\n
a candidate which significantly increases distribution of phosphatidylcholine or galactosylceramide in the inner leaflet of plasma membrane compared to control is selected as an agent promoting a biological function of the TMEM16 family member as a lipid scramblase, and a candidate which significantly decreases distribution of phosphatidylcholine or galactosylceramide in the inner leaflet of plasma membrane compared to control is selected as an agent inhibiting a biological function of the TMEM16 family member as a lipid scramblase; and\n
wherein\n
the cells are human, monkey, mouse, or rabbit cells,\n
the distribution of phosphatidylserine in plasma membrane is determined by detecting the binding between phosphatidylserine exposed to the cell surface and an agent having phosphatidylserine-binding property, and\n
the distribution of phosphatidylcholine or galactosylceramide in plasma membrane is determined by utilizing a fluorescently-labeled lipid."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the lipid is selected from phosphatidylcholine or galactosylceramide when the TMEM16 family member is TMEM 16C."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the lipid is selected from phosphatidylserine, phosphatidylcholine, or galactosylceramide when the TMEM16 family member is TMEM 16D."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the lipid is selected from phosphatidylserine, phosphatidylcholine, or galactosylceramide when the TMEM16 family member is TMEM 16G."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the lipid is selected from phosphatidylserine, phosphatidylcholine, or galactosylceramide when the TMEM16 family member is TMEM 16J."],"number":5,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}